SOX2: a key player in prostate cancer progression and treatment resistance: Study
Prostate cancer remains a global health challenge, ranking as the second most common malignancy among men. While early-stage disease can be effectively managed, advanced forms-particularly metastatic castration-resistant prostate cancer (mCRPC)-pose significant therapeutic hurdles. A growing body of evidence highlights the pivotal role of SOX transcription factors, with SOX2 emerging as a central driver in tumor […]